X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ABBOTT INDIA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ABBOTT INDIA DISHMAN PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 25.1 34.6 72.5% View Chart
P/BV x 3.3 10.0 33.4% View Chart
Dividend Yield % 0.7 0.6 108.6%  

Financials

 DISHMAN PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ABBOTT INDIA
Mar-17
DISHMAN PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3745,190 7.2%   
Low Rs1294,351 3.0%   
Sales per share (Unadj.) Rs197.81,382.9 14.3%  
Earnings per share (Unadj.) Rs21.2130.2 16.3%  
Cash flow per share (Unadj.) Rs34.7137.9 25.2%  
Dividends per share (Unadj.) Rs2.0040.00 5.0%  
Dividend yield (eoy) %0.80.8 94.8%  
Book value per share (Unadj.) Rs179.9652.7 27.6%  
Shares outstanding (eoy) m80.6921.25 379.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 36.9%   
Avg P/E ratio x11.936.6 32.4%  
P/CF ratio (eoy) x7.234.6 21.0%  
Price / Book Value ratio x1.47.3 19.1%  
Dividend payout %9.430.7 30.7%   
Avg Mkt Cap Rs m20,306101,373 20.0%   
No. of employees `0000.83.1 26.9%   
Total wages/salary Rs m5,3553,453 155.1%   
Avg. sales/employee Rs Th19,252.79,531.9 202.0%   
Avg. wages/employee Rs Th6,459.51,119.9 576.8%   
Avg. net profit/employee Rs Th2,064.1897.3 230.0%   
INCOME DATA
Net Sales Rs m15,96129,387 54.3%  
Other income Rs m265576 46.0%   
Total revenues Rs m16,22629,963 54.2%   
Gross profit Rs m4,1033,973 103.3%  
Depreciation Rs m1,091164 663.8%   
Interest Rs m94420 4,629.4%   
Profit before tax Rs m2,3344,365 53.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,598 39.0%   
Profit after tax Rs m1,7112,767 61.9%  
Gross profit margin %25.713.5 190.1%  
Effective tax rate %26.736.6 73.0%   
Net profit margin %10.79.4 113.9%  
BALANCE SHEET DATA
Current assets Rs m11,01818,906 58.3%   
Current liabilities Rs m9,5176,297 151.1%   
Net working cap to sales %9.442.9 21.9%  
Current ratio x1.23.0 38.6%  
Inventory Days Days11062 177.7%  
Debtors Days Days3522 161.0%  
Net fixed assets Rs m16,3041,159 1,407.0%   
Share capital Rs m161213 76.0%   
"Free" reserves Rs m12,90713,657 94.5%   
Net worth Rs m14,51613,869 104.7%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80520,638 144.4%  
Interest coverage x3.5215.0 1.6%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.4 37.6%   
Return on assets %8.913.5 66.0%  
Return on equity %11.819.9 59.1%  
Return on capital %17.531.6 55.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9520-   
Fx outflow Rs m6970-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,7863,072 90.7%  
From Investments Rs m-1,529-1,554 98.4%  
From Financial Activity Rs m-941-898 104.8%  
Net Cashflow Rs m316621 51.0%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 7.9 46.8%  
FIIs % 12.7 0.1 12,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.1 129.2%  
Shareholders   46,261 18,270 253.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS